EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$308M
Cap. Flow %
11.53%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
3 Miscellaneous 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$430M
$580M 21.68%
11,284,280
+250,000
+2% +$7.8M
2018 Q4
10 quarters
MORF icon
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$227M 8.48%
3,951,566
+952,251
+32% +$52.4M
2019 Q2
8 quarters
ANAB icon
3
AnaptysBio
ANAB
$1.4B
$195M 7.29%
7,521,024
+369,400
+5% +$8.85M
2019 Q4
6 quarters
XNCR icon
4
Xencor
XNCR
$1.74B
$169M 6.32%
4,906,106
+5,800
+0.1% +$230K
2018 Q4
10 quarters
RLAY icon
5
Relay Therapeutics
RLAY
$3.74B
$164M 6.14%
4,487,776
+1,058,413
+31% +$34.9M
2020 Q3
3 quarters
NUVB icon
6
Nuvation Bio
NUVB
$1.64B
$128M 4.77%
13,711,517
+464,500
+4% +$5.3M
2021 Q1
1 quarter
STTK icon
7
Shattuck Labs
STTK
$535M
$96.2M 3.6%
3,318,410
+860,151
+35% +$25.1M
2020 Q4
2 quarters
RCUS icon
8
Arcus Biosciences
RCUS
$2.87B
$91.6M 3.42%
3,335,247
+1,139,355
+52% +$32.5M
2018 Q1
13 quarters
ALEC icon
9
Alector
ALEC
$210M
$88.4M 3.3%
4,242,634
+3,640,034
+604% +$68.6M
2021 Q1
1 quarter
SPRY icon
10
ARS Pharmaceuticals
SPRY
$391M
$80.9M 3.02%
2,618,036
+84,401
+3% +$2.71M
2020 Q4
2 quarters
KURA icon
11
Kura Oncology
KURA
$855M
$77.7M 2.9%
3,724,437
+31,800
+0.9% +$789K
2015 Q4
22 quarters
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$75M 2.8%
464,298
– –
2018 Q4
10 quarters
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.2B
$54.7M 2.04%
3,092,218
– –
2020 Q2
4 quarters
NRIX icon
14
Nurix Therapeutics
NRIX
$2.59B
$52.2M 1.95%
1,967,950
-51,069
-3% -$1.5M
2020 Q3
3 quarters
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$52M 1.94%
2,103,950
– –
2020 Q2
4 quarters
JANX icon
16
Janux Therapeutics
JANX
$1.05B
$35.2M 1.32%
+1,411,975
New +$31.4M
2021 Q2
0 quarters
SLDB icon
17
Solid Biosciences
SLDB
$585M
$33.7M 1.26%
613,513
– –
2020 Q4
2 quarters
GRTS icon
18
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$31.2M 1.17%
3,421,287
– –
2020 Q4
2 quarters
TBIO icon
19
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$28.9M 1.08%
1,048,976
+452,076
+76% +$8.88M
2021 Q1
1 quarter
ITOS icon
20
DELISTED
iTeos Therapeutics
ITOS
$26.6M 0.99%
1,035,864
+775,864
+298% +$18.5M
2020 Q3
3 quarters
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.02B
$26.1M 0.98%
1,224,175
– –
2021 Q1
1 quarter
KYMR icon
22
Kymera Therapeutics
KYMR
$8.88B
$25.2M 0.94%
519,416
+419,416
+419% +$18.2M
2020 Q3
3 quarters
DSGN icon
23
Design Therapeutics
DSGN
$609M
$25.1M 0.94%
1,260,019
+122,079
+11% +$3.08M
2021 Q1
1 quarter
AKUS
24
DELISTED
Akouos Inc
AKUS
$24.8M 0.93%
1,975,984
– –
2020 Q2
4 quarters
ARVN icon
25
Arvinas
ARVN
$446M
$24.8M 0.93%
321,724
+3,020
+0.9% +$210K
2021 Q1
1 quarter
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $308M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.